What it's for (Indications)
- Tramadol hydrochloride and acetaminophen combination therapy is indicated for the short-term (generally five days or less) management of moderate to moderately severe acute pain in adults.
- This fixed-dose combination offers dual-mechanism analgesia, leveraging the opioid agonist properties and monoamine reuptake inhibition of tramadol alongside the central analgesic and antipyretic effects of acetaminophen.
- Its use is typically considered when other non-opioid analgesics are insufficient or not tolerated, and the benefits of opioid analgesia outweigh the associated risks.
- Prescribers should carefully assess the patient's pain level, functional status, and potential for adverse effects before initiating therapy, emphasizing the importance of using the lowest effective dose for the shortest possible duration to mitigate risks such as dependence, addiction, and respiratory depression.
- This medication is not intended for chronic pain management due to the inherent risks associated with prolonged opioid use.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended adult dosage of tramadol hydrochloride and acetaminophen is two tablets every 4 to 6 hours as needed for pain relief, not to exceed eight tablets (equivalent to 300 mg tramadol and 2600 mg acetaminophen) per day. Each tablet typically contains 37.5 mg of tramadol hydrochloride and 325 mg of acetaminophen. For patients with creatinine clearance less than 30 mL/min, the dosing interval should be extended to not exceed two tablets every 12 hours, with a maximum of six tablets (225 mg tramadol / 1950 mg acetaminophen) per day. In patients with hepatic impairment, the recommended dosage is two tablets every 12 hours, not to exceed six tablets (225 mg tramadol / 1950 mg acetaminophen) per day, due to the increased risk of hepatotoxicity from acetaminophen and reduced tramadol clearance. Dosage must be individualized and titrated to the lowest effective dose that provides adequate pain relief while minimizing adverse reactions. Abrupt discontinuation after prolonged use can lead to withdrawal symptoms; therefore, a gradual tapering schedule is recommended. |
Safety & Warnings
Common Side Effects
- Common adverse reactions associated with tramadol hydrochloride and acetaminophen therapy include nausea, dizziness, somnolence, vomiting, constipation, and headache.
- These are primarily attributable to the tramadol component and often resolve with continued use or dose adjustment.
- More serious, but less common, side effects include respiratory depression, seizures, serotonin syndrome (especially when used with other serotonergic agents), and adrenal insufficiency.
- Cardiovascular effects such as orthostatic hypotension, syncope, and palpitations may also occur.
- Due to the acetaminophen component, hepatotoxicity is a significant concern, particularly with overdose or in patients with pre-existing liver conditions.
- Allergic reactions, including rash, pruritus, and rarely, severe skin reactions (e.
- g.
- , Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis), have been reported.
- Patients should be counselled on potential side effects and instructed to seek immediate medical attention for any severe or unexpected reactions, such as difficulty breathing, severe dizziness, or yellowing of the skin or eyes.
Serious Warnings
- Black Box Warning: Tramadol hydrochloride and acetaminophen carries several critical Black Box Warnings from the U.S. Food and Drug Administration (FDA) that necessitate careful consideration before prescribing. These include the substantial risks of addiction, abuse, and misuse, which can lead to overdose and death; a comprehensive Risk Evaluation and Mitigation Strategy (REMS) is required for opioid analgesics to address these serious risks. Life-threatening respiratory depression is a paramount concern, particularly with initiation, dose escalation, or concomitant use with other central nervous system (CNS) depressants, including benzodiazepines or alcohol. Accidental ingestion, especially by children, can result in a fatal overdose of tramadol. Furthermore, prolonged maternal use during pregnancy can lead to Neonatal Opioid Withdrawal Syndrome, which may be life-threatening if not recognized and treated. The medication's metabolism can be affected by cytochrome P450 enzymes; ultra-rapid metabolizers of CYP2D6 may experience dangerously high tramadol concentrations. The acetaminophen component also contributes to Black Box Warnings, specifically the risk of serious liver injury (hepatotoxicity), which can be fatal, and the potential for serious skin reactions such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Acute Generalized Exanthematous Pustulosis (AGEP), which can also be fatal. Prescribers must counsel patients and caregivers on these severe risks.
- Tramadol hydrochloride and acetaminophen carries significant risks, including the potential for addiction, abuse, and misuse, which can lead to overdose and death.
- Life-threatening respiratory depression is a serious concern, particularly with initial dosing, dose escalation, or concomitant use with other central nervous system (CNS) depressants like benzodiazepines or alcohol.
- The risk of serotonin syndrome increases when tramadol is co-administered with other serotonergic drugs, characterized by mental status changes, autonomic instability, and neuromuscular abnormalities.
- Seizures have been reported in patients receiving tramadol, with increased risk in those with epilepsy, a history of seizures, or concurrent use of medications that lower the seizure threshold.
- The acetaminophen component poses a risk of severe hepatotoxicity, which can be fatal, especially with doses exceeding maximum daily limits or in individuals with underlying liver disease.
- Cases of serious skin reactions, including Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Acute Generalized Exanthematous Pustulosis (AGEP), have also been reported with acetaminophen.
- Neonatal opioid withdrawal syndrome can occur in infants born to mothers physically dependent on tramadol during pregnancy.
- Patients should be warned about the risks of driving or operating heavy machinery due to potential drowsiness or dizziness.
- This medication should be used with extreme caution in patients with head injury, increased intracranial pressure, or severe renal or hepatic impairment.
How it Works (Mechanism of Action)
Tramadol hydrochloride and acetaminophen exerts its analgesic effects through a synergistic dual mechanism. Tramadol is a centrally acting synthetic opioid analgesic that functions primarily as a weak agonist at µ-opioid receptors. In addition to its opioid activity, tramadol also inhibits the reuptake of norepinephrine and serotonin, which contributes to its analgesic effects by modulating descending pain pathways in the central nervous system. This dual action provides a broader spectrum of pain relief compared to agents acting solely through opioid receptors. Acetaminophen (paracetamol), the non-opioid component, is believed to produce analgesia primarily through central mechanisms, possibly by inhibiting prostaglandin synthesis in the central nervous system (CNS) and by modulating the endogenous cannabinoid system, although its exact mechanism is not fully elucidated. Unlike NSAIDs, acetaminophen exhibits weak anti-inflammatory activity and does not cause significant peripheral prostaglandin inhibition or gastrointestinal irritation. The combination of these two agents provides enhanced pain relief, allowing for lower individual doses and potentially reduced side effects compared to higher doses of either drug used alone.
Commercial Brands (Alternatives)
No other brands found for this formula.